Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets
about
Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challengesBiosimilars entering the clinic without animal studies. A paradigm shift in the European Union.Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor.The successes and limitations of preclinical studies in predicting the pharmacodynamics and safety of cell-surface-targeted biological agents in patients.Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals.Challenges and approaches for the development of safer immunomodulatory biologics.Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.Establishment a CHO Cell Line Expressing Human CD52 Molecule.Anti-interleukin-2 receptor antibodies for the prevention of rejection in liver transplant recipients: a systematic review and meta-analysis.Nonclinical development of a biosimilar: the current landscape.Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.First Infusion Reactions are Mediated by FcγRIIIb and Neutrophils.
P2860
Q28079835-9A828B75-9B4C-48F7-9AEC-E206E798B9B5Q36214490-20D06F00-FC91-4889-A9D6-E425C2A6E128Q37138952-5A828E07-61EA-4F3F-B86B-667CF880EF7EQ37987953-B3921D2E-CB28-4048-B2AE-3C2B30F10FE6Q38061448-4DEE6345-C06C-4520-8A29-09E86FC238BEQ38093772-C8F28F73-A522-47BE-90C0-166109A03956Q38208275-94B8563E-77C7-49BA-82C7-026C0BB95AC8Q38722163-5D39F4F7-4612-48B7-A397-D0FDB35A71DEQ38998606-FB26A911-2A53-43CF-933A-B60A2BC2E794Q39464414-7E230A42-94FC-4FD0-88C5-C53D1D340C96Q46523280-94F99FA9-F132-450F-9F5E-1A104948158AQ55454180-B9192019-5F43-4988-BE3F-9711311D804A
P2860
Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Concordance of preclinical and ...... proteins: cell surface targets
@ast
Concordance of preclinical and ...... proteins: cell surface targets
@en
Concordance of preclinical and ...... proteins: cell surface targets
@nl
type
label
Concordance of preclinical and ...... proteins: cell surface targets
@ast
Concordance of preclinical and ...... proteins: cell surface targets
@en
Concordance of preclinical and ...... proteins: cell surface targets
@nl
prefLabel
Concordance of preclinical and ...... proteins: cell surface targets
@ast
Concordance of preclinical and ...... proteins: cell surface targets
@en
Concordance of preclinical and ...... proteins: cell surface targets
@nl
P2860
P1476
Concordance of preclinical and ...... proteins: cell surface targets
@en
P2093
Pauline L Martin
Peter J Bugelski
P2860
P304
P356
10.1111/J.1476-5381.2011.01811.X
P407
P577
2012-06-01T00:00:00Z